Research suggests that more than half of Americans could benefit from taking a GLP-1 RA medication. The drugs were originally designed to help manage type two diabetes, but in 2024, the Food and Drug Administration approved one GLP-1, Semaglutide, for weight loss. With that approval came a spike in prescriptions for the drugs, and a spike in calls related to GLP-1s to poison control centers. That's the focus of this episode of Stats and Stories with guests Jordan and Robert Miller.

Jordan Miller is a post-baccalaureate student, double majoring in statistics and data science and mathematics at UT San Antonio.

Robert Miller is a specialist in poison information with the South Texas Poison Center at UT San Antonio.

Rss Apple Podcaster
Podden och tillhörande omslagsbild på den här sidan tillhör The Stats + Stories Team. Innehållet i podden är skapat av The Stats + Stories Team och inte av, eller tillsammans med, Poddtoppen.